Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex.

Article date: 2012/12/27

PubMed ID: 1599987

Journal name: Psychopharmacology (ISSN: 1432-2072)

DOI: 10.1007/s00213-011-2530-y


We provide a brief heuristic overview of our preclinical and clinical studies with the SSRI-antipsychotic combination and argue that the finding that it causes similar dynamic changes in laboratory and clinical domains, specifically in GABA-A β2/3 receptor and PKC, strongly supports the hypothesis that the GABA-A receptors and their regulatory systems are involved in the molecular mechanisms underlying the clinical effectiveness of SSRI augmentation.

Author List: Danovich Lena, Weinreb Orly, Youdim Moussa B H, Silver Henry

Publication Types: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

Article Date: 2011/10/12

Substances mentioned in the article: Antidepressive Agents; Antipsychotic Agents; Receptors, GABA-A; Serotonin Uptake Inhibitors;

Mesh terms: Animals; Antidepressive Agents/administration & dosage; Antipsychotic Agents/administration & dosage; Drug Therapy, Combination; Male; Prefrontal Cortex/drug effects; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, GABA-A/physiology; Serotonin Uptake Inhibitors/administration & dosage; Treatment Outcome;

Citations: - 11147928

1599987.txt · Last modified: 2018/11/20 14:25 (external edit)